Compare FRD & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | MGNX |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 115.8M |
| IPO Year | 1995 | 2013 |
| Metric | FRD | MGNX |
|---|---|---|
| Price | $18.33 | $1.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 21.8K | ★ 546.8K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | $121,157,278.00 | ★ $149,962,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | 55.82 | ★ 155.26 |
| 52 Week Low | $12.24 | $0.99 |
| 52 Week High | $24.37 | $2.63 |
| Indicator | FRD | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 42.87 |
| Support Level | $18.54 | $1.57 |
| Resistance Level | $20.60 | $1.70 |
| Average True Range (ATR) | 1.19 | 0.07 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 12.89 | 22.68 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.